Department of Neurology, UW Medicine, University of Washington, Seattle, WA, USA.
Department of Neurology, Stanford University, Stanford, CA, USA.
Curr Treat Options Oncol. 2019 Feb 21;20(3):24. doi: 10.1007/s11864-019-0619-4.
At this time, there are no FDA-approved immune therapies for glioblastoma (GBM) despite many unique therapies currently in clinical trials. GBM is a highly immunosuppressive tumor and there are limitations to a safe immune response in the central nervous system. To date, there have been several failures of phase 3 immune therapy clinical trials in GBM. These trials have targeted single components of an antitumor immune response. Learning from these failures, the future of immunotherapy for GBM appears most hopeful for combination of immune therapies to overcome the profound immunosuppression of this disease. Understanding biomarkers for appropriate patient selection as well as tumor progression are necessary for implementation of immunotherapy for GBM.
目前，尽管有许多独特的疗法正在临床试验中，胶质母细胞瘤（GBM）仍没有获得 FDA 批准的免疫疗法。GBM 是一种高度免疫抑制性肿瘤，在中枢神经系统中安全的免疫反应存在局限性。迄今为止，已有几项针对 GBM 的 3 期免疫治疗临床试验失败。这些试验的靶点是抗肿瘤免疫反应的单一成分。从这些失败中吸取教训，GBM 免疫治疗的未来似乎最有希望通过联合免疫治疗来克服这种疾病的深度免疫抑制。了解适合患者选择和肿瘤进展的生物标志物对于 GBM 的免疫治疗的实施是必要的。
